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Abstract: Polymorphisms in the genes encoding cytochrome p450 (CYP) and thiopurine S-methyl transferase (TPMT) enzymes
catalyze the metabolic reactions of several drugs. These polymorphisms might be responsible for adverse drug reactions. Turkish
population data for these genes still needs to be elucidated. We aimed to detect the allele frequencies of thiopurine S-methyl
transferase (TPMT), cytochrome p4503A4*1B (CYP3A4*1B) and cytochrome p4503A4*3 (CYP3A5*3) gene variants in the Turkish
population. We examined the TPMT (*1, *2, *3A, *3C), CYP3A4*1B and CYP3A5*3 variant allele frequencies in a group of healthy
Turkish Caucasian blood donors by using PCR-RFLP, allele-specific PCR and direct sequencing techniques. The frequencies of four
allelelic variants of TPMT gene, are *2 (238G>C)(2.0%), *3A (460G>A and 719A>G)(1.0%), *3B (460G>A)(0.0%) and *3C
(719A>G) (1.4%). We observed CYP3A4*1B allele frequency in 1.4% and CYP3A5*3 allele frequency in 7.5% of our population.
This study provides the first analysis of TPMT, CYP3A4*1B and CYP3A5*3 mutant allele frequencies in the Turkish population.
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Introduction
Drug metabolizing enzymes participate in the
neutralizing of xenobiotics and biotransformation of
drugs. Polymorphisms in the drug-metabolizing enzyme
coding genes alter the activity of these enzymes for some
substrates (1). Cytochrome P4503A (CYP3A) mediated
metabolism is associated with drug-drug interactions and
chemically induced carcinogenesis in several cancers (2,
3). CYP3A is the most highly expressed subfamily in the
liver and small intestine tissues. The isoforms of CYP3A,
which include the CYP3A4, CYP3A5, CYP3A7 and
CYP3A43, comprise the largest portion of the liver (30%
of all CYP’s). Steroids, antidepressants, benzodiazepines,
immunosuppressive agents, macrolide antibiotics and
toxins are the most common substrates of CYP3A
enzymes (4). Moreover, dexamethasone, rifampicin and
clotrimazole increase the expression of CYP3A genes (5).
CYP proteins are encoded by distinct genes (6). CYP3A4

and CYP3A5 are the predominant hepatic p450 forms in
adults and their expression varies among individuals.
They metabolize approximately 45-60% of drugs
currently in use and their catalytic activity is important in
bioavailibility and drug-drug interactions (3, 7).
Thiopurine S-methyltransferase (TPMT) is a cytosolic
enzyme that catalyzes the S-methylation of aromatic and
heterocyclic sulfhydryl compounds like 6-mercaptopurine
(6MP), which is used to treat patients with acute
lymphoblastic leukemia (ALL), thioguanine a widely used
drug in acute myeloblastic leukemia, and azathiopurine
(AZA), which is used in rheumatic diseases effects but also
myelosuppression (8). TPMT activity is related to the
outcome and/or toxicity of therapy. Patients with
inherited very low levels of TPMT activity are at increased
risk for thiopurine-induced toxicity, when treated with
standard doses of these drugs (9).
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More than 30 single nucleotide polymorphisms have
been identified in the CYP3A4 gene. CYP3A4*1B is an A
to G transition in the 5’ flanking region of the gene, and
it has been speculated that this variant has a reduced
activity (10). Significant ethnic differences occur in the
allele frequencies of CYP3A variants (Tables 1 and 2). To
date, nine mutant TPMT alleles have been reported (11).
The wild type allele is TPMT*1, which shows high TPMT
activity, has a frequency of 90% in Caucasians, while
10% of the individuals show intermediate activity (12).
The frequencies of TPMT *2 (238G>C),, TPMT*3A
(719A>G-460G>A) and TPMT *3C (719A>G) alleles
have been demonstrated in different populations in Table
3. These alleles account more than 80% of TPMT gene in
Caucasians.

Material and Methods
Blood samples were collected from members of the
faculty and hospital staff and students (n = 148; 83
females and 65 males; age range of 16 years and 59
years (mean age, 28.7 ± 8.3)). The Institutional Review
Board approved the research, and informed consents
were obtained from all participants.
Genomic DNA was extracted from peripheral blood by
using proteinase K/salting out method. Primer design and
restriction enzyme analysis were performed according to
previous studies (13, 14). The samples without any
TPMT*2, *3A, *3B and *3C mutations were genotyped as
TPMT wild type allele (TPMT*1), the samples with one
deficient allele (TPMT*1/*2, *1/*3C, *1/*3B, *1/*3A)
were genotyped as heterozygous and the samples with
two deficient alleles (TPMT*2/*3C, *2/*3B, *3C/*3B,
*2/*3A etc.) were genotyped as homozygous. The
samples that carried both the G460A and A719G
mutations were named TPMT *3A.

Testing for the most common TPMT and CYP3A
genotypes are used to modify doses of thiopurines such
as 6-MP and AZA that are used to treat ALL and steroids,
antidepressants, benzodiazepines, immunosuppressive
agents and macrolide antibiotics respectively. There have
been no previously published studies on TPMT, CYP3A4
and CYPA5 genes in the Turkish Population. In the
current study, we investigated allele frequency of
TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, CYP3A4*1B
and CYP3A5*3 in the Turkish population.

The analysis of A→G transversion at the
5’untranslated region of CYP3A4*1B gene was
performed by a two-step PCR-based restriction fragment
polymorphism assay as described by Wandel et al. (10).
CYP3A5*3 gene was analyzed by direct sequencing as
described by Kuehl et al. (15). We performed the

Table 1. CYP3A5*3 variant allele frequencies in different populations.
Chinesea

Japanesea

Britishb

Caucasiana

African-Americana

Turkishc

(n = 366)

(n = 366)

(n = 200)

(n = 366)

(n = 366)

(n = 372)

29.0%

6.5%

5.0%

73.0%

7.5%

27.0%
a

b

Hustert et al.,

King et al.,

c

present study

Table 2. CYP3A4*1B variant allele frequencies in different populations.
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American-Africana

Caucasianb

Britishc

Finnishd

Chinesed

Turkishe

n = 80

n = 106

n = 200

n = 118

n = 108

n = 186

35.0%

6.5%

6.5%

4.2%

0.0%

1.4%

a

Kuehl et.al., 2001, b Lamba et.al., 2002, c King et.al., 2003,

d

Sata et al., 1999, e present study.
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Table 3. Frequencies of TPMT variants in different populations.
Allele frequencies (%)
Population

Reference
TPMT*2

TPMT*3A

TPMT*3C

British Caucasian(n=398)

0.5

4.5

0.3

Ameyaw et al., 1999

American Caucasian(n=564)

0.2

3.2

0.2

Hon et.al., 1999

French Caucasian(n=608)

0.7

3.0

0.4

Ganiere-Monteil et al., 2004

German Caucasian(n=2428)

0.2

4.4

0.4

Elke et al., 2004

African-American(n=496)

0.4

0.8

2.4

Hon et.al.,1999

Italian(n=206)

0.4

3.9

0.9

Rossi et.al, 2001

Japanese(n=302)

0.0

0.0

1.6

Kumagai et.al., 2001

South-east Asian(n=698)

0.0

0.0

1.0

Chang et al., 2002

Brazil(n=408)

2.2

1.5

1.0

Boson et.al., 2003

Turkish(n=296)

2.0

1.0

1.4

present study

n, observed number of alleles

sequencing in 93 individuals (46 females and 47 males)
of the population. The primers are designed according to
previously published sequences (15). Amplified fragments
were purified with PCR purification columns (Qiagen) and
sequenced on PE ABI 310 capillary sequencer, using the
Big Dye Terminator Cycle Sequencing Kit (Perkin Elmer
Kit).

Results

TPMT *2, *3A, *3B and *3C variant genotypes were
determined in 148 unrelated individuals for the Turkish
population. The individuals that carried none of these
variants were named as TPMT*1 and one hundred thirty
five samples (135 of 148 subjects) carried the TPMT
*1/*1 genotype. Six TPMT *2 heterozygotes and four
TPMT*3C heterozygotes were found in the 148 Turkish
subjects. Three samples were observed as carriers (3 of
148 subjects) of both G460A and A719G mutations and
they were named *3A. TPMT*3B variant was not
detected in Turkish subjects. The allele frequencies of
TPMT*2 (2.0%), TPMT*3A (1.0%), TPMT*3B (0.0%)
and TPMT*3C (1.4%) were given in Table 4.
We did not observe any homozygous variant for
CYP3A4*1B and CYP3A5*3 genes in the studied
population (Table 5). Four CYP3A4*1B heterozygotes in
148 subjects and fourteen CYP3A5*3 heterozygotes in

93 subjects were determined in our subjects. Allele
frequencies of CYP3A4*1B and CYP3A5*3 were 1.4%
and 7.5% respectively, in the Turkish Population.

Discussion
It has been demonstrated that the presence of the
mutant alleles is predictive of the enzyme activity, so that
heterozygous individuals have intermediate activity and
homozygous individuals have low activity, although a
variability can seen between these groups (16-18).
TPMT*2 was the most common mutation (45.4%)
among the examined variants and the other mutations
were TPMT*3C (31.8%), TPMT*3A (22.7%) and
TPMT*3B (0.0%). These alleles have been identified as
responsible for enzyme deficiency and account for more
than 80% of the TPMT gene in Caucasians (11).
The current study has documented that the overall
frequency of TPMT alleles is 4.4% in Turkish Population.
TPMT*2 and *3 alleles are the most common mutant
alleles in Caucasians (11). TPMT*2 was found the most
prevalent mutation among Turks as well as the Brazilian
population (19), whereas TPMT*3A seems the most
common variant in American and European Caucasians
(11, 20). TPMT*3C allele is the only mutation found in
Japanese (21) and the south-east Asians (22).
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Table 4. Allele frequencies of common TPMT variants in a group of 148 Turkish subjects.
Allele

SNP position

Aminoacid substitution

Frequency (%)
(n=296)

TPMT*1

wild type

TPMT*2

238G>C

Ala80Pro

2.0

TPMT*3A

460G>A and 719A>G

Ala154Thr and Tyr240Cys

1.0

TPMT*3B

460G>A

Ala154Thr

0.0

TPMT*3C

719A>G

Tyr240Cys

1.4

94.6

None of analysed mutations was detected.
*n, observed number of alleles

Table 5. Allelic frequencies of CYP3A4*1B and CYP3A5*3 variants in the Turkish population.
CYP3A4(n=296)

Allele frequency

CYP3A5(n=186)

CYP3A4*1

CYP3A4*1B(-288A>G)

CYP3A5*1

CYP3A5*3(6986A>G)

98.6%

1.4%

92.5%

7.5%

*n, observed number of alleles

The CYP3A subfamily plays a particularly important
role, between 45% and 60% of all currently used drugs
are substrates for CYP3A enzymes (6). Our findings
showed that in the Turkish population, CYP3A5*3 allele
frequency is similar to the previously reported data,
whereas CYP3A4*1B allele frequency seems to be lower
than other studies that were reported before. For
comparison, the CYP3A5 allele was detected in 29%
Japanese, 6.5% British, 73% African-American and
7.5% Turkish (23, 24) and the CYP3A4 allele was in
0.0% Chinese, 6.5% British, 65% African-American and
1.4% Turkish (15, 24-26).
Given that all major TPMT and CYP3A mutant alleles
are present in the Turkish population, it would be good
clinical practice for the rational use of individual drug
therapy. This current study is the first to elucidate the
genetic basis for TPMT, CYP3A4 and CYP3A5 enzyme
deficiencies in Turkish Population.
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